Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 9/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.96 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.48 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.48 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 3/20 | 0.63 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531984 | 0.98 | SIGMAR1 (1.00) | HTR2CSIGMAR1QDPRMAPKAPK2HTR6 | |
| SCHEMBL14704899 | 0.86 | SIGMAR1 (0.79) | HTR2CSIGMAR1QDPRMAPKAPK2HTR6 | |
| Hydrochloric Acid SCHEMBL28678896 | 0.82 | HTR2C (0.70) | HTR2CSIGMAR1QDPRHTR6MAPT | |
| Hydrochloric Acid SCHEMBL2158640 | 0.82 | HTR2C (0.69) | HTR2CSIGMAR1QDPRINPPL1 | |
| Hydrochloric Acid SCHEMBL16423171 | 0.81 | HTR2C (0.68) | HTR2CSIGMAR1QDPRHTR6INPPL1 | |
| Hydrochloric Acid SCHEMBL3788041 | 0.80 | HTR2C (1.00) | HTR2CSIGMAR1QDPRHTR6MAPT | |
| Hydrochloric Acid SCHEMBL25217174 | 0.80 | HTR2C (1.00) | HTR2CSIGMAR1QDPRHTR6MAPT | |
| Hydrochloric Acid SCHEMBL7290341 | 0.80 | HTR2C (0.67) | HTR2CSIGMAR1QDPRHTR6MAPT | |
| Hydrochloric Acid SCHEMBL730625 | 0.80 | HTR2C (0.67) | HTR2CSIGMAR1QDPRHTR6HTR2A | |
| SCHEMBL14704901 | 0.80 | SIGMAR1 (0.69) | HTR2CSIGMAR1QDPRMAPKAPK2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568399-B1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| US-20200148716-A1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10570165-B2 | Aziridine spinosyn derivatives and methods of making | AGRIMETIS, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3568399-A1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | Agrimetis, LLC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20180291053-A1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS, LLC (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-09-06 | — | — | US | disclosed |
| WO-2018132288-A1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS, LLC (US) | 2018-07-19 | — | — | WO | disclosed |
| EP-3328843-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-06 | — | — | EP | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-0436157-B1 | Quinazoline derivatives and their preparation | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-08-23 | — | — | EP | disclosed |
| US-5304560-A | Treating CNS disorders; dopamine receptor antagonist | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-19 | — | — | US | disclosed |
| US-5296487-A | Dopamine antagonist for nervous system disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| US-5264438-A | Dopamine receptor agonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0556342-A1 | NEW 1-AZABICYCLOALKANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | GYOGYSZERKUTATO INTEZET K.V. (HU) | 1993-08-25 | — | — | EP | disclosed |
| WO-1992007854-A1 | NEW 1-AZABICYCLOALKANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | GYÓGYSZERKUTATÓ INTÉZET KV. (HU) | 1992-05-14 | — | — | WO | disclosed |
| EP-0481342-A1 | Quinazoline derivatives and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
| EP-0436157-A1 | Quinazoline derivatives and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-10 | — | — | EP | disclosed |
| WO-1991008200-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS AS ACTIVE AGENTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1991-06-13 | — | — | WO | disclosed |
| WO-1989005799-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár RT (HU) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251437-A1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC6, HDAC2 | HTR2C 2704/4885SIGMAR1 1712/4885HTR6 1142/4885 |
| US-10570165-B2 | Aziridine spinosyn derivatives and methods of making | AAAS, AZI2, NISCH | HTR2C 621/4885SIGMAR1 3754/4885HTR6 208/4885 |
| US-20200148716-A1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AAAS, AZI2, NISCH | HTR2C 621/4885SIGMAR1 3754/4885HTR6 208/4885 |
| US-20180291053-A1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AAAS, AZI2, NISCH | HTR2C 621/4885SIGMAR1 3754/4885HTR6 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.